Clinical DevelopmentThe company's fibroblast treatment shows potential for superior wound healing and timely wound size reduction in diabetic foot ulcer treatment.
Market OpportunityChronic wound care represents a sizable market with $28B in healthcare spending with nearly 2 million patients experiencing venous leg ulcers and diabetic foot ulcers annually.
Regenerative Medicine PotentialFibroblasts have significant potential in regenerative medicine as they share a host of overlapping properties with stem cells, making them a potentially less expensive and more accessible cell therapy for patients.